Long non-coding RNAs HERH-1 and HERH-4 facilitate cyclin A2 expression and accelerate cell cycle progression in advanced hepatocellular carcinoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
    • Abstract:
      Background: The advanced hepatocellular carcinoma (HCC), such as the recurrent tumor after liver transplantation (LT), is an obstacle of HCC treatment. The aim of this study was to discover the underlying mechanism of HCC progression caused by non-coding RNAs (ncRNAs).
      Methods: To this end, we investigated the selected patient cohort of matching primary and recurrent HCC after receiving LT. The recurrent tumors after LT were regarded as clinical models of the advanced HCC. Microarrays were used to profile lncRNA and mRNA expression in HCC recurrent and primary tissue samples. The mRNA profile characteristics were analyzed by bioinformatics. Two cell lines, HepG2 and QGY-7703, were used as HCC cell models. The protein-coding potential, length, and subcellular location of the interested lncRNAs were examined by bioinformatics, Northern blot, fluorescent in situ hybridization (FISH), and quantitative RT-PCR (qRT-PCR) assays. HCC cell proliferation was detected by CCK-8, doubling time and proliferation marker gene quantitation assays. DNA replication during the cell cycle was measured by EdU/PI staining and flow cytometry analyses. Promoter activity was measured using a luciferase reporter assay. Interactions between DNA, RNA, and protein were examined by immunoprecipitation and pull-down assays. The miRNA-target regulation was validated by a fluorescent reporter assay.
      Results: Both lncRNA and mRNA profiles exhibited characteristic alterations in the recurrent tumor cells compared with the primary HCC. The mRNA profile in the HCC recurrent tissues, which served as model of advanced HCC, showed an aberrant cell cycle regulation. Two lncRNAs, the highly expressed lncRNA in recurrent HCC (HERH)-1 and HERH-4, were upregulated in the advanced HCC cells. HERH-1/4 enhanced proliferation and promoted DNA replication and G1-S transition during the cell cycle in HCC cells. HERH-1 interacted with the transcription factor CREB1. CREB1 enhanced cyclin A2 (CCNA2) transcription, depending on HERH-1-CREB1 interaction. HERH-4 acted as an miR-29b/c sponge to facilitate CCNA2 protein translation through a competing endogenous RNA (ceRNA) pathway.
      Conclusions: The oncogenic lncRNA HERH-1/4 promoted CCNA2 expression at the transcriptional and post-transcriptional levels and accelerated cell cycle progression in HCC cells. The HERH-1-CREB1-CCNA2 and HERH-4-miR-29b/c-CCNA2 axes served as molecular stimuli for HCC advance.
      (© 2021. The Author(s).)
    • References:
      Br J Cancer. 2015 Feb 3;112(3):532-8. (PMID: 25584485)
      Genomics Proteomics Bioinformatics. 2017 Jun;15(3):177-186. (PMID: 28529100)
      Ann Surg Oncol. 2011 May;18(5):1243-50. (PMID: 21327457)
      Nat Rev Cancer. 2018 Jan;18(1):5-18. (PMID: 29170536)
      World J Gastroenterol. 2015 Oct 21;21(39):11185-98. (PMID: 26494973)
      Eur J Gastroenterol Hepatol. 2019 Sep;31(9):1148-1156. (PMID: 31247632)
      Mol Cell. 2011 Nov 18;44(4):667-78. (PMID: 21963238)
      Hepatobiliary Surg Nutr. 2018 Dec;7(6):429-439. (PMID: 30652087)
      Oncotarget. 2016 Apr 12;7(15):19824-39. (PMID: 26918346)
      Nat Rev Cancer. 2012 Apr 19;12(5):323-34. (PMID: 22513401)
      Genetics. 2013 Mar;193(3):651-69. (PMID: 23463798)
      Trends Genet. 2017 Oct;33(10):665-676. (PMID: 28870653)
      Brief Bioinform. 2016 Jan;17(1):106-16. (PMID: 26041786)
      Expert Rev Gastroenterol Hepatol. 2015 Jun;9(6):765-79. (PMID: 25827821)
      Curr Protoc Bioinformatics. 2016 Jun 20;54:1.30.1-1.30.33. (PMID: 27322403)
      Nature. 2014 Jan 16;505(7483):344-52. (PMID: 24429633)
      Dig Dis. 2015 Sep;33(5):635-41. (PMID: 26398186)
      Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W429-34. (PMID: 16845041)
      Nucleic Acids Res. 2020 Jan 8;48(D1):D87-D92. (PMID: 31701148)
      Oncogene. 2006 Aug 28;25(38):5220-7. (PMID: 16936740)
      Nature. 2012 Sep 6;489(7414):101-8. (PMID: 22955620)
      Bioinformatics. 2002 Feb;18(2):333-4. (PMID: 11847087)
      Semin Liver Dis. 2015 Feb;35(1):3-11. (PMID: 25632930)
      Nat Biotechnol. 2006 Sep;24(9):1140-50. (PMID: 16964228)
      World J Gastroenterol. 2016 Sep 14;22(34):7645-59. (PMID: 27678348)
      Cell. 2007 Jul 13;130(1):101-12. (PMID: 17632058)
      Nucleic Acids Res. 2005 Nov 27;33(20):e179. (PMID: 16314309)
      Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7154-9. (PMID: 23536298)
      Wiley Interdiscip Rev RNA. 2019 May;10(3):e1525. (PMID: 30761752)
      Nat Rev Clin Oncol. 2018 Feb;15(2):81-94. (PMID: 29115304)
      Biochem Pharmacol. 2000 Oct 15;60(8):1179-84. (PMID: 11007956)
      Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
      Cell. 2011 Aug 5;146(3):353-8. (PMID: 21802130)
      United European Gastroenterol J. 2019 Jul;7(6):838-849. (PMID: 31316788)
      Med Oncol. 2012 Sep;29(3):1810-6. (PMID: 21678027)
      Transpl Int. 2016 Mar;29(3):369-80. (PMID: 26697811)
      Genomics Proteomics Bioinformatics. 2016 Feb;14(1):42-54. (PMID: 26883671)
      J Clin Invest. 2016 Aug 1;126(8):2775-82. (PMID: 27479746)
      BMC Med Genomics. 2016 Apr 08;9:18. (PMID: 27059462)
      Mol Cell. 2019 Aug 22;75(4):741-755.e11. (PMID: 31324449)
      Elife. 2015 Aug 12;4:. (PMID: 26267216)
    • Contributed Indexing:
      Keywords: Cancer progression; Cell cycle; Hepatocellular carcinoma; Long non-coding RNA
    • Accession Number:
      0 (Biomarkers, Tumor)
      0 (CCNA2 protein, human)
      0 (Cyclin A2)
      0 (RNA, Long Noncoding)
    • Publication Date:
      Date Created: 20210827 Date Completed: 20211018 Latest Revision: 20211018
    • Publication Date:
      20240105
    • Accession Number:
      PMC8390207
    • Accession Number:
      10.1186/s12885-021-08714-7
    • Accession Number:
      34445994